title: [Irritated bowel syndrome: clinicomorphological aspects of treatment with melaxen].
abstract: The purpose of the study was to evaluate the clinical effectiveness of melatonin (melaxen, Unipharm, USA), and its influence on the ultrastructural and histological features on the colon mucosa (CM) in patients with irritable bowel syndrome (IBS) corresponding to Rome criteria II. Twenty-one patients with IBS were examined before and after the end of the therapy (one month upon the beginning of treatment). All the patients had non-specific morphological changes in the CM, which were more pronounced during exacerbation and less significant during remission. The study showed that in terms of stool normalization and sleep improvement in IBS patients the combination of basic therapy and melaxen was more effective than either the combination of basic therapy and psychotropic drugs or basic therapy alone. Basic therapy plus melaxen is comparable in its effects to basic therapy plus psychotropic drugs in terms of coping with pain syndrome and dyspeptic syndrome in IBS patients, the normalization of their mental status and life quality improvement. The treatment of IBS with melaxen proved to be more effective than other therapies, which was proved by histological and electron microscopic studies of the CM.
authors.forename: F I
authors.initials: FI
authors.lastname: Komarov
authors.forename: N T
authors.initials: NT
authors.lastname: Raĭkhlin
authors.forename: S I
authors.initials: SI
authors.lastname: Rapoport
authors.forename: N K
authors.initials: NK
authors.lastname: Malinovskaia
authors.forename: L A
authors.initials: LA
authors.lastname: Voznesenskaia
authors.forename: A I
authors.initials: AI
authors.lastname: Rumiantseva
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001706:Biopsy; D003106:Colon / Q000187:drug effects / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000648:ultrastructure; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008550:Melatonin / Q000627:therapeutic use*; D008875:Middle Aged; D011788:Quality of Life; D012812:Sigmoidoscopy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D008550:Melatonin